Altimmune (ALT) Return on Capital Employed (2011 - 2026)

Altimmune (ALT) has 16 years of Return on Capital Employed data on file, last reported at 32.69% in Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 32.69%, up 3821.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 32.69% (up 3821.0% YoY), and the FY2025 annual result was 48.55%, up 1417.0% from the prior year.
• Return on Capital Employed improved to 32.69% in Q1 2026 per ALT's latest filing, from 40.35% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 32.69% in Q1 2026 and troughed at 77.5% in Q4 2024.
• A 5-year average of 53.92% and a median of 52.37% in 2023 frame the typical range for Return on Capital Employed.
• The sharpest annual moves came in 2022 and 2026: Return on Capital Employed sank 2712 bps in 2022, then soared 3821 bps in 2026.
• A 5-year view of Return on Capital Employed shows it stood at 44.08% in 2022, then slipped by 23 bps to 54.36% in 2023, then plunged by 43 bps to 77.5% in 2024, then surged by 48 bps to 40.35% in 2025, then rose by 19 bps to 32.69% in 2026.
• Business Quant data shows ALT's Return on Capital Employed at 32.69% in Q1 2026, 40.35% in Q4 2025, and 47.17% in Q3 2025.